From startups to global corporations — here's what you need to know about paying remote workers. Photo via Getty Images

In the years leading up to the COVID-19 pandemic, the U.S. job market saw a steady increase in hybrid and remote work opportunities. The mass adoption, however, of a more “flexible workplace” — and the teleconferencing technologies necessary to make it a widespread option — was not yet commonplace. And in many industries, the idea of offering employees the ability to work from home several days a week — or more — brought up concerns over loss of productivity and loss of control.

Although the tech industry was more open to the idea of hybrid and remote work (and offered the option to a growing number of employees) — it wasn’t until pandemic lockdowns sent millions of workers home in early 2020, that the landscape of the American workplace, as a whole, changed forever.

For those workers whose positions allowed them to work from home, there were challenges related to balancing remote work with remote learning and overcoming Wi-Fi and teleconferencing glitches.

To minimize the time necessary to adapt to a whole new way of doing business, tech companies stepped in — utilizing their innovation to power hybrid work spaces and provide applications and other means to facilitate virtual collaboration and solve network connectivity and security concerns.

As employees — in tech and other industries — adapted to the “new normal,” a few things became clear:

  • Productivity — in many cases — increased
  • Hybrid and remote work option are viable for the long term
  • Employees value flexibility (in many cases, they value it over a higher salary)
  • Remote work offered up a whole new world of opportunities — no matter where you live or where your business is located

For employees and employers alike, hybrid/remote work broke down geographic barriers — allowing tech companies to hire qualified talent anywhere in the world and providing employees with the ability to relocate to hometowns that offer lower living expenses, a better quality of life, or the opportunity to be closer to family in other cities or states.

This new geographic freedom also brought up a very important question — especially for tech companies based in regions with a high cost of living:

As we open job opportunities up to remote workers across the country, do we pay employees based on their location (cost of living) or the job description?

According to an April 2022 article in Fast Company, “Several large tech companies, including Meta and Google, announced that employees moving to cities with a lower cost of living would be taking a pay cut. For instance, Google employees moving to cheaper cities or outside of the office hub could see a cut—as high as 25 percent —in their compensation.”

While Reuters’ “Pay cut: Google employees who work from home could lose money,” by Danielle Kaye noted that “…smaller companies including Reddit and Zillow have shifted to location-agnostic pay models, citing advantages when it comes to hiring, retention and diversity.”

We have clients on both sides of this equation, but it is important to note that asking an employee to take a pay cut might be risky in a competitive labor market. Making a decision on location-based pay versus job-based pay should consider all factors involved to help determine what's best for your workforce and your business.

We outlined a few pros and cons for each pay model. As you make decisions for your own organization, it’s a good idea to consider the following:

Pros and cons of location-based pay

  • PRO: Workers are paid wages commensurate with where they live and can expect to cover state and local taxes, housing, and other expenses associated with that location.
  • PRO: A company can save on wage costs, mainly if remote workers live in more affordable markets.
  • CON: Employees who live in less expensive housing markets make less for the same work done by co-workers in locations with a higher cost of living.
  • CON: Companies may experience higher turnover rates if they impose a pay cut policy that penalizes employees who move to smaller, more rural locations.

Pros and cons of job-based pay

  • PRO: Employees who live in a lower-cost area can opt for a larger home and more expensive "extras" and save more than if they choose to live in a city with a higher cost-of-living.
  • PRO: A job-based compensation structure can be more straightforward to administer because it focuses on allocating pay systematically and not on where employees live, which may shift over time.
  • CON: Employees with specialized skills and expertise who live in more expensive geographic markets may not be compensated as generously as those who work for competitors with location-based pay policies. This can diminish a company's recruiting competitive edge.
  • CON: Employees who move to locations with increased legislative and regulatory requirements can create increased operational costs for employers as they comply with new laws in the new location.
  • CON: Job-based pay structures can increase a company's wage (operating) costs.

------

Lisa Bauer is director of compliance services at G&A Partners.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Greentown Labs names Lawson Gow as its new Houston leader

head of hou

Greentown Labs has named Lawson Gow as its Head of Houston.

Gow is the founder of The Cannon, a coworking space with seven locations in the Houston area, with additional partner spaces. He also recently served as managing partner at Houston-based investment and advisory firm Helium Capital. Gow is the son of David Gow, founder of Energy Capital's parent company, Gow Media.

According to Greentown, Gow will "enhance the founder experience, cultivate strategic partnerships, and accelerate climatetech solutions" in his new role.

“I couldn’t be more excited to join Greentown at this critical moment for the energy transition,” Gow said in a news release. “Greentown has a fantastic track record of supporting entrepreneurs in Houston, Boston, and beyond, and I am eager to keep advancing our mission in the energy transition capital of the world.”

Gow has also held analyst, strategy and advising roles since graduating from Rice University.

“We are thrilled to welcome Lawson to our leadership team,” Georgina Campbell Flatter, CEO of Greentown Labs, added in the release. “Lawson has spent his career building community and championing entrepreneurs, and we look forward to him deepening Greentown’s support of climate and energy startups as our Head of Houston.”

Gow is the latest addition to a series of new hires at Greentown Labs following a leadership shakeup.

Flatter was named as the organization's new CEO in February, replacing Kevin Dutt, Greentown’s interim CEO, who replaced Kevin Knobloch after he announced that he would step down in July 2024 after less than a year in the role.

Greentown also named Naheed Malik its new CFO in January.

Timmeko Moore Love was named the first Houston general manager and senior vice president of Greentown Labs. According to LinkedIn, she left the role in January.

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

Houston foundation grants $27M to support Texas chemistry research

fresh funding

Houston-based The Welch Foundation has doled out $27 million in its latest round of grants for chemical research, equipment and postdoctoral fellowships.

According to a June announcement, $25.5 million was allocated for the foundation's longstanding research grants, which provide $100,000 per year in funding for three years to full-time, regular tenure or tenure-track faculty members in Texas. The foundation made 85 grants to faculty at 16 Texas institutions for 2025, including:

  • Michael I. Jacobs, assistant professor in the chemistry and biochemistry department at Texas State University, who is investigating the structure and thermodynamics of intrinsically disordered proteins, which could "reveal clues about how life began," according to the foundation.
  • Kendra K. Frederick, assistant professor in the biophysics department at The University of Texas Southwestern Medical Center, who is studying a protein linked to Parkinson’s disease.
  • Jennifer S. Brodbelt, professor in chemistry at The University of Texas at Austin, who is testing a theory called full replica symmetry breaking (fullRSB) on glass-like materials, which has implications for complex systems in physics, chemistry and biology.

Additional funding will be allocated to the Welch Postdoctoral Fellows of the Life Sciences Research Foundation. The program provides three-year fellowships to recent PhD graduates to support clinical research careers in Texas. Two fellows from Rice University and Baylor University will receive $100,000 annually for three years.

The Welch Foundation also issued $975,000 through its equipment grant program to 13 institutions to help them develop "richer laboratory experience(s)." The universities matched funds of $352,346.

Since 1954, the Welch Foundation has contributed over $1.1 billion for Texas-nurtured advancements in chemistry through research grants, endowed chairs and other chemistry-related ventures. Last year, the foundation granted more than $40.5 million in academic research grants, equipment grants and fellowships.

“Through funding basic chemical research, we are actively investing in the future of humankind,” Adam Kuspa, president of The Welch Foundation, said the news release. “We are proud to support so many talented researchers across Texas and continue to be inspired by the important work they complete every day.”

New Houston biotech co. developing capsules for hard-to-treat tumors

biotech breakthroughs

Houston company Sentinel BioTherapeutics has made promising headway in cancer immunotherapy for patients who don’t respond positively to more traditional treatments. New biotech venture creation studio RBL LLC (pronounced “rebel”) recently debuted the company at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Rima Chakrabarti is a neurologist by training. Though she says she’s “passionate about treating the brain,” her greatest fervor currently lies in leading Sentinel as its CEO. Sentinel is RBL’s first clinical venture, and Chakrabarti also serves as cofounder and managing partner of the venture studio.

The team sees an opportunity to use cytokine interleukin-2 (IL-2) capsules to fight many solid tumors for which immunotherapy hasn't been effective in the past. “We plan to develop a pipeline of drugs that way,” Chakrabarti says.

This may all sound brand-new, but Sentinel’s research goes back years to the work of Omid Veiseh, director of the Rice Biotechnology Launch Pad (RBLP). Through another, now-defunct company called Avenge Bio, Veiseh and Paul Wotton — also with RBLP and now RBL’s CEO and chairman of Sentinel — invested close to $45 million in capital toward their promising discovery.

From preclinical data on studies in mice, Avenge was able to manufacture its platform focused on ovarian cancer treatments and test it on 14 human patients. “That's essentially opened the door to understanding the clinical efficacy of this drug as well as it's brought this to the attention of the FDA, such that now we're able to continue that conversation,” says Chakrabarti. She emphasizes the point that Avenge’s demise was not due to the science, but to the company's unsuccessful outsourcing to a Massachusetts management team.

“They hadn't analyzed a lot of the data that we got access to upon the acquisition,” explains Chakrabarti. “When we analyzed the data, we saw this dose-dependent immune activation, very specific upregulation of checkpoints on T cells. We came to understand how effective this agent could be as an immune priming agent in a way that Avenge Bio hadn't been developing this drug.”

Chakrabarti says that Sentinel’s phase II trials are coming soon. They’ll continue their previous work with ovarian cancer, but Chakrabarti says that she also believes that the IL-2 capsules will be effective in the treatment of endometrial cancer. There’s also potential for people with other cancers located in the peritoneal cavity, such as colorectal cancer, gastrointestinal cancer and even primary peritoneal carcinomatosis.

“We're delivering these capsules into the peritoneal cavity and seeing both the safety as well as the immune activation,” Chakrabarti says. “We're seeing that up-regulation of the checkpoint that I mentioned. We're seeing a strong safety signal. This drug was very well-tolerated by patients where IL-2 has always had a challenge in being a well-tolerated drug.”

When phase II will take place is up to the success of Sentinel’s fundraising push. What we do know is that it will be led by Amir Jazaeri at MD Anderson Cancer Center. Part of the goal this summer is also to create an automated cell manufacturing process and prove that Sentinel can store its product long-term.

“This isn’t just another cell therapy,” Chakrabarti says.

"Sentinel's cytokine factory platform is the breakthrough technology that we believe has the potential to define the next era of cancer treatment," adds Wotton.